Safety Evaluation of Subchronic Oral Administration of Oleuropein and its Semisynthetic Peracetylated Derivative

Saverio Massimo Lepore1, Francesca Trimboi1, Marilena Celano1, Manuela Oliverio1, Roberta Francesca De Rose1, Giovanni Loprete1, Nicola Costa1, Carla Di Loreto2, Giuseppe Damante2, Sonia Bonacci1, Antonio Procopio1, Diego Russo1*, Domenico Britti1

Introduction

Olive tree (*Olea europaea*) leaves have been widely used in traditional remedies in European and Mediterranean countries for centuries. They contain many potentially bioactive compounds that possess several pharmacological properties[1,2]. Among them, secoiridoid oleuropein (OLE) constitutes up to 6 – 9% of dry matter in the leaves. It is also present in considerable amounts in drupes, while its concentration in virgin olive oil is significantly reduced due to the enzymatic degradation that occurs during olive processing[1-4]. Due to their health benefits, oleuropein, oleuropein derivatives, and seco-phenolic compounds are all considered to be important elements that make extra virgin olive oil a staple part of the Mediterranean diet. Also, the compounds include the ability to scavenge reactive oxygen species (ROS)[5-7], to inhibit the proliferation of several tumor cell lines[5,8-11], and also to protect against cardiovascular diseases[3,12-15] and metabolic disorders as Diabetes mellitus[16-19]. In addition, they are effective in experimental models of age-related disorders, such as neurodegenerative diseases[14,20,21]. By using an innovative extractive method that employs renewable sources of primary matter and adopts sustainable synthetic strategies, we obtained OLE and some acetylated derivatives in good yields and very mild conditions[22,23]; interestingly, the latter compounds have shown an improved capacity to permeate the molecular membrane, in addition to their ‘drug likeness’[22]. Moreover, we have recently demonstrated that peracetylated oleuropein (Ac-OLE) possesses *in vitro* an antioxidant and a growth-inhibitory activity that is even stronger than OLE when acting against both breast and thyroid cancer cell lines[8,9]. While the absence of toxicity of oleuropein is well established[1,5,11], very little is known about the *in vivo* effects of its peracylated derivative. In this work, we investigated the comprehensive subchronic effects regarding the

Abstract

Olive leaf extracts are a natural source of phenolic compounds; this includes secoiridoid oleuropein (OLE), which has been widely investigated for its beneficial health effects. Previous in vitro studies have revealed antiproliferative and antioxidant activity in peracylated oleuropein that is even stronger than oleuropein itself. The aim of the present study was to evaluate the effect of the subchronic administration of oleuropein, and for the first time, also evaluate its semisynthetic peracetylated derivative (peracetylated oleuropein, Ac-OLE). OLE and Ac-OLE were orally administered to male C57BL/6JolaHsd mice at doses of 20 mg/kg/day for 15 weeks. In comparison to the control group, there were no treatment-related clinical signs of toxicity, nor were there any changes to note in body weight, food consumption, hematological and clinical chemistry parameters, or liver weight. Moreover, the histological examination of the liver, kidney, and lungs did not reveal any morphological alterations. These findings demonstrate that no adverse effects may be attributed to the subchronic oral administration of 20 mg/kg/day of Ac-OLE. However, additional experiments are necessary to clarify the action of the peracylated compound in light of its therapeutic use.

Keywords: Oleuropein; Peracetylated oleuropein; Dietary supplement; Subchronic toxicity
oral administration of Ac-OLE as compared to OLE in C57BL/6JOLAhsd mice.

Materials and Methods

Study design

Animal care was in compliance with Italian regulations regarding the protection of animals used for experimental and other scientific purposes (D.M. 116/92) as well as complying with the European Union regulations (O.J. of E.C. L 358/1 12/18/1986). All experiments were conducted in accordance with the Guide for the Care and Use of Laboratory Animals. All efforts were made to minimize the number of animals used in this study and their suffering.

Compounds

OLE and Ac-OLE were obtained as described\(^{[23]}\). Briefly, dried olive leaves from cultivar Coratina of O. Euro-
paea were extracted in water under microwave-irradiation, and OLE was isolated as a pure compound from the aqueous ex-
tract after evaporation under reduced pressure and washing three times with acetone. Ac-OLE was achieved after the chemical modification of OLE following a patented synthetic method\(^{[23]}\), and was subsequently used for biological tests after chromato-
graphic purification. OLE and its peracetylated derivative were extensively characterized by El, S.N., H-NMR and LC/ESI-MS, as previously described\(^{[23]}\).

Animals

4-week-old male C57BL/6JOLAhsd mice were purchased from Harlan Laboratories S.r.l. (Udine, Italy). Mice were placed in quarantine for 2 weeks in Animal Facility conditions and observed for clinical signs on daily basis. Then, they were divided into three groups (n = 5 in each group) of equal average body weight. One group was used as control, while the other two were used as treatment groups. The average weight at the time of treatment was 19.4 ± 1.2 g for all mice. All animals were housed in a temperature (20 - 22°C) and humidity (64%) controlled animal room and maintained on a 12:12 h light/dark cycle. The water was provided ad libitum throughout the acclimatization and study periods.

Treatment, clinical examination, body weight, naso-anal length, girth waist, and feed consumption

Animal grouping was done using the method of body weight stratification and randomization. The grouping was done 1 day prior to the beginning of treatment. The body weight of mice after grouping was recorded and analyzed statistically for mean body weight to rule out the statistically significant difference. The group of control mice (n = 5 each) was fed with a normal diet, while the other two groups of mice (n = 5 each) were fed with the same diet with an additional administration of OLE and Ac-OLE (20 mg/kg/day)\(^{[12,15,16,18,27-29]}\) for 15 consecutive weeks (6 days a week).

Every day, OLE and Ac-OLE were freshly prepared from a condensed stock solution before administration and added to diet pellet; also, it was checked that each mouse had ingested the food containing the daily dose of OLE and Ac-OLE. Water was used as a vehicle for the preparation of OLE, while corn oil was used as a vehicle for the preparation of Ac-OLE. Animals of all groups received the same vehicle used for the peracetylated compound and also had free access to food and water. The dose for each animal was calculated based on the weekly body weight of the mice. At the end of the treatment, all of the mice were sacrificed. Throughout the study period, the mice were observed daily for clinical signs of toxicity and mortality/morbidity. Body weight, naso-anal length and girth waist were measured weekly. To measure the total caloric intake, pre-
weighed food was put into the cage and weighed a week later. Hematological, clinical chemistry and liver weighing were performed at termination. Histological examination was conducted on liver, lung, and kidney tissues from all groups.

Blood collection

Mice were fasted for 4 h before blood collection, and water was provided during the fasting period. Mice were deeply anesthetized with a combination of Tiletamine hypochloride and Zoletil hypochloride (Zoletil, Virbac, France) at a dosage of 80 mg/kg, and Medetomidine hydrochloride (Domitor, Ori-
con Corporation, Espoo, Finland) at a dosage of 6.6 mg/kg. This anesthetic was administered by intraperitoneal injection. Blood samples were obtained by cardiac venipuncture and were collected into blood collection tubes (Vacuette, Greiner Bio-One GmbH, Kremsmunster, Austria) containing K\(_2\)-EDTA.

Hematology and Clinical chemistry

Blood samples were analysed using a Hematology Analyzer ADVIA 2120 (Siemens Healthcare Diagnostics S.r.l., Milan, Italy) to obtain the following hematology parameters: White Blood Cells (WBC) and leukocyte formula (a percentage of neutrophils, lymphocytes, monocytes, and eosinophils), Red Blood Cells (RBC), Hemoglobin (HGB), Hematocrit (HCT), Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Hemoglobin Concentration (MCHC), and platelet count. Subsequently, the same blood sam-

Histological Study

Immediately after sacrificing the mice, the liver, lung and kidney tissues were collected for histological studies. The whole liver was removed and weighed. The tissues were washed in a normal saline solution and immediately fixed in 10% neutral buffered formalin (Sigma-Aldrich S.r.l., Milan, Italy). The tissue samples were embedded in paraffin after dehydration through a graded ethanol series followed by xylene. Several sections (thickness 4–5 μm) from each paraffin block were cut, mounted on slides and, after deparaffinization and hydration, were stained with haematoxylin and eosin (H&E) according to the standard methods for histological assessment under light mi-

microscopy.

www.ommegaonline.org

2

J Pharm Pharmaceutics | volume 3: issue 1
**Statistical analysis**

Statistical analyses were performed using Sigma Plot version 12 (Systat Software Inc.) on body weight, naso-anal length, girth waist, food consumption, energy intake, liver weight, and hematological and clinical chemistry parameters. The results are expressed as means ± standard deviation (SD). A one-way ANOVA followed by Tukey multiple comparison tests was performed for different treatment groups and control group data. The differences between the groups were considered significant at p < 0.01.

**Results**

**Clinical signs, body weight, naso-anal length, girth waist and feed consumption**

There were no behavioral changes, clinical signs of toxicity, or mortality noted in any of the two groups of mice treated with OLE and Ac-OLE throughout the treatment period. The animal examination revealed a normal health status, and no abnormalities were observed during all the study period. Similarly, no significant differences were detected in body weight, naso-anal length, and girth waist measured during all the experimental periods among the groups (Table 1). The mean food consumption and energy intake were also comparable in all groups (Table 1).

**Table 1: Effects of oleuropein (OLE) and peracetylated oleuropein (Ac-OLE) on body weight, naso-anal length, girth waist, food intake, and energy intake in C57BL/6JolaHsd mice.**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Control</th>
<th>OLE (20 mg/kg/day)</th>
<th>Ac-OLE (20 mg/kg/day)</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial body weight (g)</td>
<td>20.6 ± 1.1</td>
<td>21.0 ± 1.0</td>
<td>20.2 ± 1.3</td>
<td>20.3 - 7.0</td>
</tr>
<tr>
<td>Final body weight (g)</td>
<td>29.2 ± 1.2</td>
<td>30.3 ± 1.3</td>
<td>29.3 ± 2.0</td>
<td>28.0 - 7.0</td>
</tr>
<tr>
<td>Initial naso-anal length (cm)</td>
<td>8.3 ± 0.4</td>
<td>8.9 ± 0.2</td>
<td>8.8 ± 0.4</td>
<td>8.5 - 7.0</td>
</tr>
<tr>
<td>Final naso-anal length (cm)</td>
<td>9.9 ± 0.1</td>
<td>9.9 ± 0.1</td>
<td>9.9 ± 0.1</td>
<td>9.8 - 7.0</td>
</tr>
<tr>
<td>Initial girth waist (cm)</td>
<td>6.6 ± 0.1</td>
<td>6.6 ± 0.07</td>
<td>6.3 ± 0.1</td>
<td>6.2 - 7.0</td>
</tr>
<tr>
<td>Final girth waist (cm)</td>
<td>7.8 ± 0.03</td>
<td>7.7 ± 0.3</td>
<td>7.7 ± 0.3</td>
<td>7.6 - 7.0</td>
</tr>
<tr>
<td>Initial food intake (g/week)</td>
<td>19.0 ± 1.2</td>
<td>18.2 ± 1.3</td>
<td>17.2 ± 1.8</td>
<td>17.0 - 7.0</td>
</tr>
<tr>
<td>Final food intake (g/week)</td>
<td>20.8 ± 0.8</td>
<td>20.4 ± 1.1</td>
<td>20.0 ± 1.2</td>
<td>20.0 - 7.0</td>
</tr>
<tr>
<td>Initial energy intake (Kcal/week)</td>
<td>58.9 ± 3.8</td>
<td>56.4 ± 4.0</td>
<td>53.3 ± 5.5</td>
<td>52.0 - 7.0</td>
</tr>
<tr>
<td>Final energy intake (Kcal/week)</td>
<td>64.5 ± 2.6</td>
<td>63.2 ± 3.5</td>
<td>62.0 ± 3.8</td>
<td>61.0 - 7.0</td>
</tr>
</tbody>
</table>

**Hematology**

There were no treatment-related toxicological signs in all of the hematology parameters analyzed in the blood samples collected at the end of the treatment period in any of the treated groups of mice (Table 2). Furthermore, we did not observe significant differences in the hematology parameters following the administration of OLE and Ac-OLE as compared to the control group in this strain of mice.

**Table 2: Effects of oleuropein and peracetylated oleuropein on hematological parameters in C57BL/6JolaHsd mice**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Units</th>
<th>Control</th>
<th>OLE (10³/L)</th>
<th>Ac-OLE (10³/L)</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC</td>
<td>(10³/L)</td>
<td>2.40 ± 0.50</td>
<td>2.20 ± 0.80</td>
<td>2.60 ± 0.90</td>
<td>2.30 - 7.0</td>
</tr>
<tr>
<td>RBC</td>
<td>(10³/L)</td>
<td>8.60 ± 1.10</td>
<td>8.80 ± 0.30</td>
<td>8.40 ± 0.40</td>
<td>8.40 - 10.20</td>
</tr>
<tr>
<td>HGB</td>
<td>(mmol/L)</td>
<td>8.31 ± 0.12</td>
<td>8.25 ± 0.37</td>
<td>8.00 ± 0.68</td>
<td>7.80 – 9.00</td>
</tr>
<tr>
<td>HCT</td>
<td>(fraction of %)</td>
<td>0.42 ± 0.06</td>
<td>0.44 ± 0.02</td>
<td>0.42 ± 0.03</td>
<td>0.42 – 0.50</td>
</tr>
<tr>
<td>MCV</td>
<td>(fL)</td>
<td>48.30 ± 1.20</td>
<td>49.60 ± 1.10</td>
<td>50.80 ± 0.80</td>
<td>48.00 - 52.00</td>
</tr>
<tr>
<td>MCH</td>
<td>(pg/cell)</td>
<td>14.60 ± 0.10</td>
<td>14.90 ± 0.40</td>
<td>15.30 ± 0.70</td>
<td>14.30 - 15.30</td>
</tr>
<tr>
<td>MCHC</td>
<td>(g/L)</td>
<td>304 ± 7.50</td>
<td>301 ± 5.20</td>
<td>302 ± 13.20</td>
<td>286 - 308</td>
</tr>
<tr>
<td>Platelets</td>
<td>(10³/L)</td>
<td>1183.20 ± 71.40</td>
<td>1057.20 ± 119.00</td>
<td>1020.30 ± 49.20</td>
<td>980 - 1390</td>
</tr>
<tr>
<td>Neutrophils</td>
<td>(%)</td>
<td>7.40 ± 1.80</td>
<td>16.20 ± 6.20</td>
<td>6.70 ± 2.70</td>
<td>2 - 34</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>(%)</td>
<td>87.60 ± 1.10</td>
<td>80.60 ± 5.60</td>
<td>85.20 ± 1.50</td>
<td>59 - 97</td>
</tr>
<tr>
<td>Monocytes</td>
<td>(%)</td>
<td>0.80 ± 0.20</td>
<td>1.50 ± 0.40</td>
<td>1.10 ± 0.20</td>
<td>0 - 6</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>(%)</td>
<td>1.60 ± 0.50</td>
<td>2.30 ± 0.10</td>
<td>1.50 ± 0.50</td>
<td>0 - 2</td>
</tr>
</tbody>
</table>

**Clinical chemistry**

Table 3 shows the clinical chemistry parameters analyzed from the blood samples collected at the end of the treatment. There were no significant differences in both the triglyceride and total cholesterol levels in mice treated with OLE and Ac-OLE.
as compared to control group. We found a significant difference (p < 0.01) between the control and treatment groups regarding the LDL fraction in OLE-; however, this was not the case in the Ac-OLE-treated mice. A significant increase in AST was noted in Ac-OLE-treated mice, which resulted in an approximately 2.5 fold difference, which was higher than those detected in the OLE-treated and control groups. However, the AST levels in this group of animals were still within the normal range of values expected for this strain of mice.

Table 3: Effects of oleuropein and peracetylated oleuropein on serum chemistry parameters in C57BL/6JOlaHsd mice.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Units</th>
<th>Control</th>
<th>OLE</th>
<th>Ac-OLE</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholesterol</td>
<td>mmol/L</td>
<td>2.81 ± 0.16</td>
<td>3.03 ± 0.06</td>
<td>2.79 ± 0.16</td>
<td>1.13 – 3.26</td>
</tr>
<tr>
<td>HDL</td>
<td>mmol/L</td>
<td>2.58 ± 0.23</td>
<td>2.74 ± 0.11</td>
<td>2.48 ± 0.24</td>
<td>1.32 – 2.65</td>
</tr>
<tr>
<td>LDL</td>
<td>mmol/L</td>
<td>0.36 ± 0.07</td>
<td>0.50 ± 0.02**</td>
<td>0.45 ± 0.06</td>
<td>0.36 – 0.80</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>mmol/L</td>
<td>1.16 ± 0.23</td>
<td>0.95 ± 0.20</td>
<td>1.30 ± 0.11</td>
<td>1.22 – 6.59</td>
</tr>
<tr>
<td>ALT</td>
<td>U/L</td>
<td>36.50 ± 4.80</td>
<td>36.40 ± 7.90</td>
<td>39.30 ± 1.50</td>
<td>13.30 - 80.20</td>
</tr>
<tr>
<td>AST</td>
<td>U/L</td>
<td>107.30 ± 6.10</td>
<td>134.80 ± 23.80</td>
<td>339.30 ± 82.60**</td>
<td>40.80 - 510.60</td>
</tr>
</tbody>
</table>

Abbreviations: Ac-OLE = peracetylated oleuropein; ALT = alanine aminotransferase; AST = aspartate aminotransferase; HDL = high density lipoproteins; LDL = low density lipoproteins; OLE = oleuropein. Reference ranges were calculated on the data published in Mouse Database Phenomena (Jackson Laboratory) (http://phenome.jax.org) as mean ± 1.96 SD except for ALT and AST, for which reference ranges were calculated as percentile (2.5th – 97.5th). ** Statistically significant compared to the control group (p < 0.01).

Histopathology

No changes were noted regarding liver weight among the groups following treatment with OLE and Ac-OLE (data not shown). As shown in (Figure 1), some sections of mouse liver revealed a preserved lobular structure; also, the liver cells showed nuclei of varied shapes and sizes. No other changes were observed. The lung and kidney tissues demonstrated a normal architecture in all the groups. Some proximal tubular cells in the kidneys showed vacuolization. No microscopic abnormalities were detected in any of the study groups (Figure 1).

Discussion

In this study, we demonstrated that the oral administration to C57BL/6JOlaHsd male mice of oleuropein, and also, for the first time, its peracetylated derivative at levels up to 20 mg/kg/day for 15 weeks was not associated with adverse effects. The analysis of the general conditions and appearance of the animals, or their growth, naso-anal length, girth waist, food consumption, hematology, clinical chemistry, liver weight, and histopathology clearly showed that OLE and Ac-OLE do not interfere with the normal metabolism of animals, as revealed by the absence of any significant differences in the above mentioned parameters. The only significant difference (p < 0.01) observed between the control and treatment groups regards the LDL fraction in OLE-, though this is
not the case in the Ac-OLE-treated mice. An increase of this parameter was noted when compared to the control animals group; however, the values remain within the normal laboratory range. Also, the serum levels of AST resulted in a significant increase in the Ac-OLE-treated mice; again, they were still within the normal range, so these changes may be considered as incidental biological variations and not treatment-related adverse effects. Such conclusions are supported by the histological analysis, which confirmed the absence of any abnormalities in the tissues of all of the treated animals. To the best of our knowledge, this is the first report regarding the influence of OLE and its peracetylated derivative treatment in vivo on hematology parameters. Both OLE and Ac-OLE did not induce any variation on mice hematology, which thus confirms the absence of subchronic toxicity for these two molecules. Recent reports have suggested the potential improvements concerning the OLE effect by protecting the molecule through its peracytlation. In previous studies, we have shown that Ac-OLE has a stronger anti-proliferative effect than OLE in the experimental models of tumor cells in vitro. Also in a very recent study, we demonstrate the beneficial effects of Ac-OLE at the same dose (20 mg/kg/day) in the prevention of hepatic steatosis, hyperinsulinemia and weight gain in mice fed with high fat cafeteria diet.

Such a chemical modification has been previously demonstrated to improve its permeability, while still maintaining the biological activity of the parent compound; this is probably owed to the extensive deacetylation by carboxylesterases. Deacetylation can take place either within the cell, upon absorption of the acetylated molecule, or in the extracellular space created by the secreted esterases. In addition, Procopio et al. have demonstrated the increased anti-inflammatory activity of Ac-OLE as compared to OLE both in vitro as a COX-1 and COX-2 inhibitor, and also in vivo as a protecting agent against the carragenen-induced paw edema in mice. Looking at these data as a whole thus suggests the potentiality to take advantage of the properties of this compound, by using it as additive in fatty foods or beverages. In conclusion, the present findings demonstrate that peracetylated oleuropein at the dose studied herein does not produce any toxic signs or clinically evident symptoms following subchronic oral administration. In the animals treated with Ac-OLE, there were no remarkable histological signs, or blood and serum chemical alterations. The effects of administering varied dosages of Ac-OLE will be analyzed in further studies in view of the potential use of this compound. Therefore, our preliminary results suggest promising alternatives for exploring the therapeutic and pharmacological use of this new molecule, as well as the investigation of its use as an additive for fatty functional foods.

Acknowledgments
This work was supported by a donation in the memory of Carmelo Stillitani to the UMG Foundation. Saverio Massimo Lepore is supported by a co-financed grant from the European Commission, the European Social Fund, and the Calabria Region. English has been edited by FirstEditing.com

Conflict of interest
The authors declare that they have no conflict of interest.

References


